What is happening at DIA Canadian Annual Meeting

• Regulatory Track

Gain a clearer understanding of Canada’s regulatory landscape through our regulatory track. You’ll hear about Health Canada’s modernization initiatives with complementary perspectives from industry on advanced therapeutic products (ATPs), medical devices, good manufacturing practices (GMP) virtual inspections, pediatric medicines, and international collaborations.

• Clinical Track

Today, modern biopharmaceutical and device products are advancing at an unprecedented speed. Sessions in this track will focus on clinical research development and operations for industry. Those interested in this track will gain an understanding of Health Canada’s approach to the modernization of clinical trial regulations, including case studies of how patients have contributed to resource development and how decentralized trials have the potential to transform the way we conduct clinical research. Take your level of understanding a step further and explore our other sessions including an industry perspective on good clinical practices (GCP) in relation to clinical trial site GCP audits and clinical trial compliance (CTC) inspections. Our attendees in this track will be able to gain real-world insights into the benefits and challenges of incorporating real-world data and real-world evidence into a whole range of decisions about clinical trials.

• Pharmacovigilance Track

  As a new edition to our programming this year, our pharmacovigilance track will provide a comprehensive overview of Canada’s regulatory environment in the field of clinical safety and pharmacovigilance for biopharmaceutical products and medical devices. Our pharmacovigilance track will kick off with an overview from representatives of various regulatory agencies, where they’ll share lessons learned from COVID-19 and their thoughts on the future challenge of risk-management planning in a post-pandemic world. Subsequent sessions will cover topics such as good pharmacovigilance practices (GVP) inspections, post-market surveillance, the use of artificial intelligence in pharmacovigilance, and general data protection regulation (GDPR) and its implications.

Upon completion of registration, participants will gain access to the following:

• Live Event Access
• Presentation Slides
• Access to recorded sessions, on demand for 4 months post event

As global events continue to accelerate the shift to digital meeting formats, the ways in which we collaborate have also evolved. Here are three key reasons to consider attending a virtual DIA Specialty Event!

We are pleased to present numerous networking opportunities during the annual conference:

• October 19 | 2:15-2:45PM ET – Coffee Corner hosted by i4i inc.: XML PM – Canada Joins the Growing Global Movement to Strengthen Patient Health and Safety Through More Structured Product Information – Click here to RSVP
• October 20 | 9:15-10:00AM ET – Round Table Session Hosted by Innomar Strategies: Drug Submissions Relying on Third-Party Data/Literature Based Submissions for Prescribing Medicines: An Update – Click here to RSVP